FDA OKs 50th & 51st anti-retroviral drugs

Aug 14, 2007

The U.S. Food and Drug Administration has tentatively approved nevirapine tablets and a pediatric medication used to treat the human immunodeficiency virus.

The FDA said the pediatric triple-fixed dose combination tablet of lamivudine, stavudine and nevirapine is the first fixed dose anti-HIV product designed to treat children under the age of 12 years.

The two drugs mark the 50th and 51st AIDS-related drugs approved or tentatively approved for purchase under the President's Emergency Plan for AIDS Relief.

The fixed dose combination comprises a complete HIV regimen taken twice daily and can also be dissolved in water for children who cannot swallow tablets. The FDA said the fact all three drugs are combined into one tablet that can be stored, distributed and administered easily is a significant advance in the treatment of children infected with HIV.

The FDA said its tentative approval means although existing patents or other factors prevent the sale of the products in the United States, the medications meets all U.S. manufacturing quality and clinical safety and efficacy requirements, helping ensure AIDS patients abroad can receive the same quality of medications as Americans.

Copyright 2007 by United Press International

Explore further: Benzodiazepine sedatives linked to higher rates of mortality compared to propofol

add to favorites email to friend print save as pdf

Related Stories

Bone marrow-on-a-chip unveiled

May 05, 2014

The latest organ-on-a-chip from Harvard's Wyss Institute for Biologically Inspired Engineering reproduces the structure, functions and cellular make-up of bone marrow, a complex tissue that until now could ...

Recommended for you

Viagra ads target women for first time

2 hours ago

The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial in America that targets the less-obvious sufferers of the sexual condition: women.

User comments : 0